BNT163 Herpes Vaccine

Chewing Away Herpes Infection

Karen McClorey Hackett — Wed, 23 Apr 2025 17:27:15 +0000

Reviewer:

Herpes simplex virus (HSV) is one of the causes of infectious blindness in Western countries, with no preventive vaccine available as of April 2025. The absence of a vaccine for HSV underscores the urgent need for innovative approaches that target reducing viral loads at the sites of transmission.

Recently, researchers from Penn Dental Medicine, in collaboration with colleagues in Finland, have addressed this issue in a study published in Molecular Therapy.

Henry Daniell, W.D. Miller Professor at Penn Dental Medicine, and collaborators tested the ability of a chewing gum made from lablab beans, Lablab purpureus, which naturally contain an antiviral trap protein (FRIL), to neutralize two herpes simplex viruses (HSV-1 and HSV-2).

This study evaluated the neutralization of viruses using a natural viral FRIL formulated in clinical-grade chewing gum. FRIL is highly stable in the lablab bean powder (683 days) and in chewing gum (790 days), and fully functional (794 days) when stored at ambient temperature.

They passed the bioburden test with no aerobic bacteria and yeasts/molds, and with a minimal moisture content of 1.28–5.9%.

Bean gum extracts trapped HSV-1/HSV-2 75–94% in a dose-dependent manner through virus self-aggregation.

The mastication simulator released over 50% of FRIL within 15 minutes of chewing the bean gum.

In plaque reduction assays, >95% neutralization of H1N1 and H3N2 required ∼40 mg/mL of bean gum, HSV-1 160 mg/mL, and HSV-2 74 mg/mL of bean gum for 1,000 copies/mL of virus particles.

"A broad-spectrum antiviral protein (FRIL) present in a natural food product (bean powder) to neutralize not only human flu viruses but also avian (bird) flu is a timely innovation to prevent their infection and transmission," Daniell stated in a press release on April 2, 2025.

These researchers wrote, 'a 2000 mg bean gum tablet has more than adequate potency for clinical evaluation and is safe with no detectable levels of glycosides.'

'These observations bode well for evaluating bean gum in human clinical studies to minimize virus infection and transmission.'

This is essential research as the cost of herpes infections is a measurable drain on society. The economic losses associated with herpes infection can be substantial, considering the lifelong nature of the disease.

A study published in 2024 estimated that HSV-2 ($31.2 billion) and HSV-1 ($4 billion) infection-related healthcare expenditures and productivity losses.

As of April 23, 2025, various herpes vaccine candidates are undergoing clinical trials, but none have been approved by the U.S. Food and Drug Administration (FDA).

Sub Title:

Herpes vaccine candidates are conducting research in April 2025

Reference:

Debulking influenza and herpes simplex virus strains by a wide-spectrum anti-viral protein formulated in clinical grade chewing

Image:

Google News Keywords:

health, vaccines, vaccinations

Featured:

Fact checked:

Thursday, April 24, 2025 - 06:30

Image Caption:

Pixabay 2025

Herpes Vaccine Availability Is Aspirational in 2025

Karen McClorey Hackett — Wed, 25 Dec 2024 16:45:24 +0000

Reviewer:

Robert Carlson, MD

With about 20% of young adults infected with one of the herpes simplex viruses (HSV) in 2024, the World Health Organization (WHO) recently raised awareness of the related costs and vaccine candidate landscape.

On December 11, 2024, the WHO revealed that the Global Health Sector Strategy on HIV, viral hepatitis, and sexually transmitted infections for 2022-2030 highlighted the cost of genital herpes infections. The WHO reaffirmed that it is also working to advance research and develop new prevention tools, such as vaccines.

Dr. Meg Doherty, Director of Global HIV, Hepatitis, and Sexually Transmitted Infections Programs for the WHO, commented on December 11, 2024, "Better herpes prevention and treatment options are urgently needed to reduce transmission....."

WHO estimates that over 200 million people aged 15 to 49 suffered at least one such symptomatic episode in 2020. In addition to sores, genital herpes can, on occasion, lead to serious complications, including neonatal herpes.

Economic losses due to genital herpes infection can be significant when considering the lifelong nature of the disease. Furthermore, quality-of-life losses have been found to outweigh treatment spending and productivity reductions.

A study published in July 2024 showed that both genital HSV-2 ($31.2 billion) and HSV-1 ($4 billion) infection-related healthcare expenditures and productivity loss were estimated in 2016.

According to the U.S. CDC, HSV-1 often causes oral herpes, resulting in cold sores or fever blisters on or around the mouth. Most people with oral herpes get it during childhood or young adulthood from non-sexual contact with saliva.

Unfortunately, genital herpes has become common in the U.S. CDC estimates show there are over 500,000 new genital herpes infections annually.

Most of the time, herpes infections cause no or few symptoms. However, for some people, they lead to painful genital sores and blisters that can recur throughout life, causing significant discomfort and often requiring multiple healthcare visits.

Currently, there is no cure for herpes, although some OTC treatments can relieve symptoms.

Developing preventive and therapeutic HSV vaccines has been challenging for decades.

In 2024, the WHO published its preferred product characteristics for Alpha (α) herpesvirus vaccines and updated its pipeline review.

As of December 25, 2024, herpes vaccine candidates are based on DNA, Messenger RNA (mRNA), protein subunits, killed virus, and attenuated live virus vaccine technologies.

For example, Moderna Inc.' sInc.' vaccine candidate mRNA-1608 is an mRNA vaccine targeting HSV-2. A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608 indicates an estimated completion date of April 11, 2025.

Dr. Sami Gottlieb, Medical Officer within WHO's Sexual and Reproductive Health and Research, commented in a media release that "expanding research and investment in developing new herpes vaccines and therapies and their equitable use could play a critical role in improving the quality of life for people around the world."

As of" December 2024, the U.S. Food and Drug Administration, Brazil, Canada, China, Europe, India, Japan, and the U.K. had not authorized preventive or therapeutic herpes HSV-1 or HSV-2 vaccines. The WHO, the U.S. National Instuties of Health, and global partners launched STI Watch, a portal containing updated information on vaccine development status.

Sub Title:

Herpes vaccines could save $35 billion a year

References:

Estimated economic burden of genital herpes and HIV

20% of adults worldwide has a genital herpes infection - WHO

Estimated global and regional economic burden of genital herpes simplex virus infection among 15–49 year-olds

WHO - Global health sector strategies 2022-2030

Image:

Google News Keywords:

health, vaccines, vaccinations

Featured:

Fact checked:

Thursday, December 26, 2024 - 06:45

Image Caption:

Spending on GH treatment, wage losses due to GH, HIV cases attributable to HSV-2, related ART spending, and QALY losses due to GH in 90 LMICs, by WHO region

Herpes Prevention Has a Vaccine Development Plan

Karen McClorey Hackett — Fri, 06 Oct 2023 08:31:32 +0000

Reviewer:

Robert Carlson, MD

One of the challenges in treating Herpes simplex virus (HSV) infections is the diverse nature of clinical manifestations of the disease, wrote the U.S. National Institutes of Health in September 2023.

In many cases, symptomatic infection with HSV can lead to the development of herpetic lesions that present as cold sores or genital herpes, which are familiar sources of disease spread.

HSV infection predominantly occurs through contact with infected tissue of oral or genital mucosal surfaces, shedding the virus.

HSV can result in diverse and distinct pathology in other body tissues, including ocular keratitis, meningitis, or encephalitis.

Once a "trigger" for transition out of latency occurs, HSV reverts into its active or lytic state. Known triggers for virus reactivation include stress, sunlight, immune suppression, and various other factors.

Recent studies have shown that live virus is shed without clinically evident classic herpetic lesions.

As such, developing and improving serologic and point-of-care diagnostics remains a research priority.

HSV infections are primarily treated with antivirals such as acyclovir (or valacyclovir), which can reduce the frequency and intensity of outbreaks of herpetic lesions if started early during the lytic cycle.

A prophylactic herpes vaccine that can prevent infection or a therapeutic vaccine for individuals already infected with HSV that could reduce recurrences and/or shedding would be crucial in mitigating the public health impact of herpes simplex viruses.

To address and coordinate efforts to facilitate HSV research, an NIH-wide HSV Working Group, led by the National Institute of Allergy and Infectious Diseases (NIAID), was established.

This group consists of scientific and policy experts from NIAID, the National Institute on Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Minority Health and Health Disparities, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Eye Institute.

This effort aligns with the ongoing Sexually Transmitted Infections (Diseases) National Strategic Plan.

To advance NIH HSV research objectives, the NIH HSV Working Group organized this plan into four strategic priorities:

improving fundamental knowledge of HSV biology, pathogenesis, and epidemiology;
accelerating research to improve HSV diagnosis;
enhancing strategies to treat and cure HSV and
advancing research to prevent HSV infection.

These interdependent priorities form the framework of the NIH strategy to advance our understanding of HSV-1 and HSV-2 and help accelerate the development of innovative vaccines.

As of October 2023, there are several herpes vaccine candidates conducting clinical research.

These vaccines are based on DNA, modified mRNA, protein subunit, killed virus, and attenuated live virus vaccine technologies.

One vaccine candidate is Moderna Inc.'s mRNA-1608, which aims to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity.

The mRNA-1608-P101 phase 1 clinical trial launched on September 6, 2023, and is forecasted to be completed in June 2025.

As of October 6, 2023, the U.S. Food and Drug Administration and agencies in Europe, Canada, China, India, and the U.K. had not authorized herpes prevention or therapeutic vaccines.

However, the NIH and global partners launched STI Watch, a portal containing updated information on vaccine development status.

Sub Title:

US NIH Strategic Plan for Herpes Vaccine Research 2023-2030

References:

Strategic Plan for HERPES SIMPLEX VIRUS Research

NIH STI National Strategic Plan 2021–2025

Image:

Age Groups:

Adult

Google News Keywords:

herpes, vaccinations

Featured:

Fact checked:

Saturday, October 7, 2023 - 06:30

Image Caption:

by Vic Wag

Strategic Plan for Herpes Research Includes Vaccines

Karen McClorey Hackett — Wed, 20 Sep 2023 17:52:20 +0000

Reviewer:

Robert Carlson, MD

To advance the clinical research into herpes simplex virus (HSV) infections, the U.S. National Institutes of Health (NIH) today released the Strategic Plan for HSV.

An NIH-wide HSV Working Group was formed in October 2022 to develop this plan, informed by feedback from more than 100 representatives of the research and advocacy communities and stakeholders.

The innovative plan published on September 19, 2023, outlines an HSV research framework with four strategic priorities: improving fundamental knowledge of HSV biology, pathogenesis, and epidemiology; accelerating research to improve HSV diagnosis; improving strategies to treat HSV while seeking a curative therapeutic, and, advancing research to prevent HSV infection.

Additionally, this plan aligns with ongoing national efforts, including the Sexually Transmitted Infections National Strategic Plan.

To date, there are no HSV vaccines approved by the U.S. Food and Drug Administration (FDA).

While research advances have resulted in several therapeutics, the effectiveness of these treatments in reducing symptoms and viral transmission varies widely.

In addition, current treatment strategies require active virus replication, making them ineffective against latent HSV infection.

However, Moderna recently reaffirmed it is developing the mRNA-1608 vaccine candidate to reduce the burden of HSV lesions based on its world-class mRNA technology.

Moderna's mRNA platform offers potential advantages in efficacy, development speed, production scalability, and reliability.

HSV can cause recurring blisters or sores, and in severe cases, HSV may lead to life-threatening or long-term complications, typically in the central nervous system. Neonatal herpes, if left untreated, is fatal in 60% of cases.

HSV-1 and HSV-2 are among the most common viral infections in the U.S.

Up to 80% of people between the ages of 14 and 49 years live with HSV-1, and more than 10% live with HSV-2, says the NIH.

Furthermore, HSV is a leading cause of viral encephalitis—brain inflammation from a viral infection—and infectious blindness worldwide.

The NIH anticipates that this plan will serve as a foundation for research, public health, and medical communities to work collaboratively to reduce the burden of HSV-1 and HSV-2.

Carolyn Deal, Ph.D., chief of the Enteric and Sexually Transmitted Infections Branch in NIAID's Division of Microbiology and Infectious Diseases, is available at niaidnews@niaid.nih.gov to comment on the significance and implementation of the plan.

Sub Title:

Herpes Accelerate Development including vaccines

References:

Strategic Plan for Research on Herpes Simplex Virus 1 and 2

U.S. NIH STI National Strategic Plan Overview

Image:

Google News Keywords:

Herpes, vaccinations

Featured:

Fact checked:

Thursday, September 21, 2023 - 07:00

Image Caption:

U.S. NIAID September 2023

U.S. NIH Herpes Strategic Plan Seeks Proposals

Karen McClorey Hackett — Mon, 24 Apr 2023 19:27:20 +0000

Reviewer:

Holly Lutmer PharmD

Robert Carlson, MD

Over the past decade, the United States has witnessed alarming increases in rates of sexually transmitted infections (STIs), amounting to a public health crisis.

The consequences of the STI epidemic are enormous, wrote the U.S. HHS.

When left untreated, STIs can lead to long-term, irreversible health outcomes such as chronic pelvic pain, infertility, adverse pregnancy outcomes, neonatal death, and congenital abnormalities.

While there are vaccines for Hepatitis, HPV, Mpox, and many STIs lack preventive and/or therapeutic vaccines.

To address one STI, the National Institute of Allergy and Infectious Diseases (NIAID) recently issued a Notice announcing a Request for Information (RFI) inviting comments and suggestions on the U.S. National Institutes of Health's (NIH) key strategic approaches to develop a Herpes Simplex Virus (HSV) Strategic Plan.

Announced on April 21, 2023, this RFI is an effort by multiple Institutes and Centers to enable the NIH's strategic plan to be structured around four research areas, as noted below.

Priority 1: Improve fundamental knowledge of HSV biology, pathogenesis, and epidemiology

Enhance fundamental knowledge of HSV biology, including but not limited to viral interactions with host cells and mechanisms of replication and transport; fundamental aspects of innate and adaptive immune response to HSV; HSV disease pathogenesis in multiple organ systems, including the skin, reproductive tract, eye, and the peripheral and central nervous systems; and the critical drivers of disease transmission.

Characterize host and pathogen drivers that underlie dynamics of HSV latency and reactivation.

Improve understanding of diverse pathophysiology of HSV infection, including neonatal infection and the role of mucosal immunity to reduce genital and orolabial infection and disease; and a deeper understanding of the neurologic impact of HSV infection, including herpes simplex encephalitis, post-herpetic neuropathic pain, post-herpetic autoimmune encephalitis (i.e., post-HSV NMDARE), and potential associations with neurodegenerative disorders such as Alzheimer's disease.

Explore epidemiology of and co-morbidities associated with HSV infection

Improve and develop new in vitro and in vivo models that reflect human disease

Priority 2: Accelerate research to improve diagnosis by developing improved biomarkers and technologies for herpes diagnosis; Improve sensitivity and specificity of serologic tests that can be made commercially; Support research to improve point-of-care diagnostics.

Priority 3: Improve strategies to treat and cure HSV by identifying candidates for the elimination of virus or functional cure; Advance the development of novel treatment strategies, including strategies for preventing HSV entry into the central nervous system and for reducing sequelae of HSV encephalitis; Evaluate the safety and efficacy of treatment strategies in diverse populations and age groups; and Optimize therapy to minimize shedding and transmission.

Priority 4: Advance research to prevent HSV infection by supporting research to identify immune correlates of protection for HSV1 and HSV2; Advance the development of promising prophylactic vaccines; Support clinical trials to test new evaluation of therapies, diagnostics, and vaccines (therapeutic and prophylactic).

This NIAID RFI seeks input from stakeholders throughout the scientific research community and the general public regarding the proposed framework.

As of April 24, 2023, the U.S. FDA has not approved any herpes vaccine candidate.

Other STI vaccine news is posted by Precision Vaccinations.

Sub Title:

HSV clinical trials for therapeutic and prophylactic vaccines gains NIH support

References:

Inviting Comments and Suggestions on NIH’s Herpes Simplex Virus Strategic Plan

U.S. HHS STI National Strategic Plan: 2021–2025

Image:

Google News Keywords:

Herpes, HSV, vaccines

Featured:

Fact checked:

Wednesday, April 26, 2023 - 06:00

Image Caption:

by Jatinder Jeetu

Herpes Infection Reduces Your Quality of Life

Karen McClorey Hackett — Thu, 06 Apr 2023 10:54:29 +0000

Reviewer:

Robert Carlson, MD

Holly Lutmer PharmD

A recent study confirmed Genital herpes (GH) is a common sexually transmitted disease associated with adverse health outcomes, which can now be measured in lifetime quality-adjusted life years lost (QALYs).

Published by The Lancet Regional Health Americas on February 7, 2023, this study calculated the average QALYs in the United States is about 18 days of life for one person.

The average number of QALYs lost per GH infection for people aged 18–49 years due to genital HSV-1 and HSV-2 was 0.01 (95% UI 0.01–0.02) and 0.05 (95% UI 0.02–0.09), respectively.

And the burden of genital HSV-1 is higher among women, while the burden of HSV-2 is higher among men.

Furthermore, the QALYs lost per neonatal herpes infection were estimated to be 7.93 (95% UI 6.63–9.19).

At the population level, the total estimated lifetime QALYs lost due to GH infections acquired in 2018 was 33,100 (95% UI 12,600–67,900) due to GH in adults and 3,140 (95% UI 2,260–4,140) due to neonatal herpes.

GH also leads to a financial burden, especially on families with neonates who develop neurological impairment due to neonatal HSV infections.

Adult GH's direct lifetime medical costs were estimated at $972 per treated case. In contrast, the lifetime costs of managing neonates with neurological sequelae varied from $21,000 to $570,000 per child, according to the severity of the condition.

Furthermore, these researchers did not include the indirect effects of GH, such as the increased risk of the acquisition of HIV.

Results from this U.S. Centers for Disease Control and Prevention study can be used to compare the burden of GH to other sexually transmitted diseases, wrote these researchers.

On a per-infection basis, the estimated average number of QALYs lost due to GH (0.05 QALYs) is smaller than that due to HIV (5.80 QALYs), syphilis (0.09 QALYs), and gonorrhea (among women, 0.09 QALYs).

While the burden of GH is higher than that of per gonorrhea infection among men (0.0015-0.002 QALYs) and per case of genital warts (0.024 QALYs).

At the population level, the estimated total quality-of-life burden due to GH in the US (33,100 QALYs) exceeds that of syphilis (13,300 QALYs), mainly due to the higher incidence of GH.

This study made several conservative assumptions that may underestimate the actual HSV burden.

They considered only the direct effects of genital HSV infections on the losses of QALY.

A study on HSV-2 and HIV interactions indicated that if prevalent genital HSV-2 infection increases HIV acquisition risk, 25.1% (95% UI 20.9-30.8%) of the incident, sexually-acquired HIV infections could be attributed to HSV-2 between 2019-2028.

And they did not include encephalitis as an adverse outcome in this model.

As of April 6, 2023, there is no cure for herpes, but a new, innovative treatment is approaching authorization.

AiCuris Anti-infective Cures AG's oral tablet Pritelivir is a highly potent inhibitor of HSV replication that inhibits the viral helicase-primase enzyme complex, in contrast to currently used nucleoside analogues, such as acyclovir.

Moreover, herpes vaccine candidates have not completed the approval process and are not currently commercially available.

Sub Title:

Genital herpes infections are costly

References:

Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling s

Sexually Transmitted Disease Vaccines April 6, 2023

Herpes Treatments April 2023

Image:

Age Groups:

19 21 years

Google News Keywords:

Herpes, vaccines

Featured:

Fact checked:

Sunday, April 9, 2023 - 07:30

Image Caption:

by Silviu P.

HSV Treatment Readies for Approval

Karen McClorey Hackett — Wed, 29 Mar 2023 20:27:02 +0000

Reviewer:

Robert Carlson, MD

Holly Lutmer PharmD

A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV).

As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.

Published on March 1, 2023, a peer-reviewed study disclosed Pritelivir was evaluated in five phase 1 trials, a single-ascending-dose trial, two multiple-ascending-dose trials, and others.

Pritelivir pharmacokinetics were found linear up to 480 mg following single and up to 400 mg following multiple once-daily doses.

The half-life ranged from 52 to 83 hours, and steady-state was reached between 8 and 13 days.

Maximum plasma concentration and area under the plasma concentration–time curve from time 0 to the last quantifiable concentration were 1.5- and 1.1-fold higher in female compared to male subjects.

Absolute bioavailability was 72% under fasted conditions.

Following a fatty diet, Pritelivir time to maximum concentration was 1.5 hours delayed, and maximum plasma concentration and area under the plasma concentration–time curve from time 0 to the last quantifiable concentration were 33% and 16% higher, respectively.

Pritelivir was found safe and well tolerated, up to 600 mg following single and up to 200 mg following multiple once-daily doses.

Considering a therapeutic dose of 100 mg once daily, Pritelivir demonstrated a favorable safety, tolerability, and pharmacokinetic profile in healthy subjects to support further development.

Based on these positive results, AiCuris form the basis for regulatory approval.

Previously, Germany-based AiCuris received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation in June 2020 to treat mucocutaneous HSV infection in immunocompromised patients.

This update is essential, as there are no FDA-approved herpes vaccines available. However, there are two mRNA-based vaccine candidates.

HSV treatments and preventive vaccines are in great demand.

According to the World Health Organization, an estimated 491 million people aged 15-49 years, or 13% of the world's population, live with genital herpes caused by HSV-2 infection.

While HSV-1 mainly causes lesions in the mouth area, HSV-2 manifests itself in the genital region and is usually transmitted sexually.

And in immunocompromised patients, HSV infection can lead to serious complications.

Disclosures: AiCuris Anti-infective Cures AG, a spin-off from Bayer AG, employed researchers during the trials and continued on a supervisory board.

Sub Title:

Pritelivir is a nonnucleoside helicase primase inhibitor against HSV

References:

Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects

AiCuris is opens in Germany for phase 3 study with pritelivir

Image:

Age Groups:

Young Adults

Google News Keywords:

Herpes, HSV, vaccines

Featured:

Fact checked:

Sunday, April 9, 2023 - 07:30

Image Caption:

by Siggy Nowak

Another mRNA Herpes Vaccine Candidate Launches

Karen McClorey Hackett — Wed, 21 Dec 2022 20:29:42 +0000

Reviewer:

Robert Carlson, MD

The race to produce a herpes virus vaccine heated up today with the announcement of a second mRNA-based clinical trial commencing.

Biopharmaceutical New Technologies (BioNTech) SE, a global leader in mRNA vaccines, announced that the first subject was dosed in a Phase 1 clinical research study with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.

The first-in-human trial evaluates the safety, tolerability, and immunogenicity of BNT163.

This mRNA vaccine encodes three HSV-2 glycoproteins intending to help prevent HSV cellular entry and spread, as well as counteract the immunosuppressive properties of HSVs.

Previously, Massachusetts-based Moderna Inc. announced it was developing the mRNA-1608 vaccine candidate in pre-human studies to reduce the burden of HSV lesions in May 2022.

Today's announcement is important since the U.S. Food and Drug Administration and agencies in Europe, Canada, India, and the U.K. have not Authorized or Approved any herpes prevention vaccine.

As neurotropic and neuroinvasive viruses, herpes viruses persist in the body by hiding from the immune system in the cell bodies of neurons where they reside lifelong and thus cannot be eradicated with current treatments.

"This program is part of our strategy to help address diseases with a high unmet medical need and of global health relevance by combining our new technologies, such as mRNA, and our expertise in immune engineering," said Prof. Özlem Türeci, M.D., Chief Medical Officer and Co-Founder of BioNTech, in a press release on December 21, 2022.

"BNT163 is based on three non-infectious mRNA-encoded HSV-2 glycoproteins."

"We aim to induce a broad immune response directed against multiple antigens of the virus and mobilizes various immune effectors to support virus neutralization and clearance."

In 2018, the University of Pennsylvania's Perelman School of Medicine (Penn) and BioNTech entered a research collaboration and license agreement to develop novel mRNA vaccine candidates for the prevention and treatment of various infectious diseases.

"My colleagues and I are proud to have contributed to the early development and preclinical testing of this exciting new mRNA vaccine candidate that may have the potential to prevent people from contracting the virus," commented Prof. Harvey M. Friedman, M.D., Professor of Infectious Diseases at Penn, who conducted preclinical and discovery science work on HSV and is Penn's principal investigator for the preclinical discovery and IND-enabling studies.

Herpes Simplex Virus-1 (HSV-1) and Herpes Simplex Virus-2 (HSV-2) cause two highly prevalent viral infections globally, says the World Health Organization.

Up to 95% of the global population is estimated to be infected by herpes, with most of the infections remaining asymptomatic.

Symptoms of herpes include painful blisters or ulcers that can recur over time.

HSV-1 is mainly transmitted by oral contact and causes lesions around the mouth, but in some cases can also lead to genital infections and respective lesions.
HSV-2 is a sexually transmitted disease that causes genital herpes. Both viruses are highly contagious and can also be transmitted during childbirth. Infections with HSV-2 further increase the risk of acquiring and transmitting HIV infections.

Located in Germany, Biopharmaceutical New Technologies is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms to develop novel biopharmaceuticals rapidly.

Additional herpes vaccine candidate development news is posted at PrecisionVaccinations.com/Herpes.

PrecisionVaccinations publishes fact-checked, research-based vaccine information manually curated for mobile readers.

Sub Title:

BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration

References:

BioNTech Vaccine Candidate BNT163

Investigational Vaccine Designed to Prevent Genital Herpes Lesions

mRNA-1608 Herpes Vaccine

WHO - herpes

Image:

Google News Keywords:

Herpes, BNT163, vaccine

Featured:

Fact checked:

Thursday, December 22, 2022 - 06:00

Image Caption:

by David Mark